Prediction and measurement of diuretic responsiveness after oral administration of furosemide to healthy dogs and dogs with congestive heart failure

Kerry A. Loughran1 | Éva Larouche-Lebel1 | Terry Huh1 | Jeffrey M. Testani2 | Veena S. Rao2 | Mark A. Oyama1,3

1Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
2Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
3Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Abstract

Background: In human patients, cumulative urine volume (uVol) and urine sodium (uNa) can be predicted using spot urine samples and these quantitative measures help detect low diuretic responsiveness (LDR).

Hypothesis/objectives: Formulas using spot urine samples predict cumulative uVol and uNa output after oral administration of furosemide to dogs.

Animals: Eight healthy dogs, 6 dogs with congestive heart failure (CHF).

Methods: Prospective interventional study. Spot urine samples at 180 and 270 minutes after furosemide (3 mg/kg PO) were used to predict cumulative uVol and uNa output over 7 hours. Differentiation of dogs fulfilling predefined criteria for LDR was examined using receiver operating characteristic (ROC) curves.

Results: Predicted uNa output at 180 minutes ($r = 0.763$, [95% confidence interval [CI], 0.375-0.923], $P = .002$) and 270 minutes ($r = 0.816$, [95% CI, 0.503-0.940], $P < .001$) was highly correlated to 7-hour uNa output. Predicted uVol at 180 minutes ($r = 0.598$, [95% CI, 0.098-0.857], $P = .02$) and 270 minutes ($r = 0.791$, [95% CI, 0.450-0.931], $P < .001$) was moderately correlated to 7-hour uVol. Predicted uNa using 180-minute (area under the curve [AUC], 0.933 [95% CI, 0.804-1.000]) and 270-minute (AUC, 0.911 [95% CI, 0.756-1.000]) samples identified dogs with LDR (n = 5) with high accuracy.

Conclusions and Clinical Importance: Urinary Na excretion and uVol are complementary but distinct aspects of diuretic responsiveness in dogs. Quantification of diuretic

Abbreviations: AUC, area under the curve; BUN, blood urea nitrogen; CHF, congestive heart failure; LDR, low diuretic responsiveness; EFWC, electrolyte free water clearance; eGFR, estimated glomerular filtration rate; Na, sodium; RAAS, renin angiotensin aldosterone system; ROC, receiver operating characteristic; [sNa], serum sodium concentration; [sCl], serum chloride concentration; [sCr], serum creatinine concentration; uNa, urine sodium; [uNa], urine sodium concentration; [uCr], urine creatinine concentration; [uK], urine potassium concentration; uVol, urine volume.

Kerry A. Loughran and Éva Larouche-Lebel contributed equally to this study.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2020 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
Congestive heart failure (CHF) stems from a series of hemodynamic, neurohormonal, and cardiorenal responses that promote retention of water and sodium (Na) in dogs and humans. Increased total body water primarily accumulates in extracellular spaces, the bulk of which is interstitial with a lesser amount as plasma volume. Total body Na content is increased secondary to activation of the renin angiotensin aldosterone system (RAAS) and increased Na avidity in the kidney. Sodium is particularly critical in the development of congestion as it represents the primary solute that regulates extracellular water balance.

In both species, dosing is guided by clinical tenets of “maintaining patient comfort” and “relieving symptoms and reducing volume excess,” however, there are substantial limitations to this subjective approach, and quantification of diuretic effect, termed diuretic responsiveness or efficiency, is the subject of considerable recent study in humans. Measures of diuretic responsiveness include urine volume (uVol), net fluid loss, weight loss, fractional excretion of Na, and urinary sodium (uNa) excretion. In purpose-bred dogs, diuretic responsiveness in the form of uVol per mg furosemide has been examined, but data in dogs with spontaneous heart disease have not been explored. In our study, we hypothesized that a similar approach could predict cumulative uNa output and uVol over the 7 hours after oral furosemide dosing in dogs and that these metrics could identify dogs with LDR. We put particular emphasis on uNa excretion because of the primacy of Na on extracellular water balance. Our study aimed to correlate observed and predicted 7-hour uNa output and uVol using a modification of a previously developed prediction equation in healthy and CHF dogs after oral administration of furosemide, as well as to explore detection of LDR using the predicted values.

In both dogs and humans with CHF, diuretics, such as furosemide, are prescribed to counteract congestion and alleviate clinical signs. In both species, dosing is guided by clinical tenets of “maintaining patient comfort” and “relieving symptoms and reducing volume excess,” however, there are substantial limitations to this subjective approach, and quantification of diuretic effect, termed diuretic responsiveness or efficiency, is the subject of considerable recent study in humans. Measures of diuretic responsiveness include urine volume (uVol), net fluid loss, weight loss, fractional excretion of Na, and urinary sodium (uNa) excretion. In purpose-bred dogs, diuretic responsiveness in the form of uVol per mg furosemide has been examined, but data in dogs with spontaneous heart disease have not been explored. In our study, we hypothesized that a similar approach could predict cumulative uNa output and uVol over the 7 hours after oral furosemide dosing in dogs and that these metrics could identify dogs with LDR. We put particular emphasis on uNa excretion because of the primacy of Na on extracellular water balance. Our study aimed to correlate observed and predicted 7-hour uNa output and uVol using a modification of a previously developed prediction equation in healthy and CHF dogs after oral administration of furosemide, as well as to explore detection of LDR using the predicted values.

The ability to identify dogs with low diuretic responsiveness (LDR) would be helpful. Clinicians long have recognized that as CHF progresses, there often remains “persistent congestion despite adequate decongestive treatment” and this so-called diuretic resistance is associated with increased mortality and hospitalization. Between 6 and 25% of dogs with severe chronic CHF had LDR according to various criteria adapted from human medicine. Measuring diuretic responsiveness is challenging. Cumulative uVol and uNa output over multiple hours after diuretic dosing have been assiduously collected and measured in humans and experimental dogs but is not practicable in most clinical settings. Instead, prediction of total uNa output and uVol using samples taken at a prescribed time point is an attractive alternative. In healthy dogs receiving constant rate infusion of furosemide, urinary Na concentration ([uNa]) to urinary potassium concentration ([uK]) ratio ([uNa]:[uK]) strongly correlated with cumulative 5-hour urine output. In humans, a prediction equation based on renal physiological principles using spot [uNa], urine creatinine concentration ([uCr]), and serum creatinine concentration ([sCr]) taken 1 to 2 hours after administration of oral bumetanide was strongly correlated with 6-hour uNa output (r = 0.91, P < .0001) and accurately predicted poor natriuretic response. In our study, we hypothesized that a similar approach could predict cumulative uNa output and uVol over the 7 hours after oral furosemide dosing in dogs and that these metrics could identify dogs with LDR. We put particular emphasis on uNa excretion because of the primacy of Na on extracellular water balance. Our study aimed to correlate observed and predicted 7-hour uNa output and uVol using a modification of a previously developed prediction equation in healthy and CHF dogs after oral administration of furosemide, as well as to explore detection of LDR using the predicted values.

A prospective trial was designed. The study protocol was approved by the University of Pennsylvania institutional animal care and use review committee and informed owner consent was obtained. Two cohorts of dogs were recruited from clients and staff of the Veterinary Hospital of the University of Pennsylvania, including healthy dogs without previous or current history of heart or systemic disease, murmur, or receipt of cardiac drugs, and a cohort of dogs with heart disease receiving ≥3 mg/kg/d oral administration of furosemide for treatment of chronic CHF. The study involved hospital admission and administration of furosemide (3mg/kg PO) followed by measurement of uVol at 180, 270, and 420 minutes after dosing and spot sampling of serum and urine at baseline within 30 minutes prior to diuretic dosing, and at 180 and 270 minutes after dosing. The 180 and 270-minute time points were established in a pilot study of 4 dogs as the best time points to predict the maximal rate of urine production (data not shown). In the current study, the dogs were taken outside at each time point and all voided urine was collected using a variety of containers, cups, and receptacles in order to eliminate or reduce any spillage or missed urine. If the dog did not voluntarily void or had urinated prior to the time point, cystocentesis was performed and 5 to 10 mL of urine was obtained to measure the time point-specific urine electrolytes. At each time point, ultrasound of the bladder was performed with dogs in lateral recumbency and bladder volume was calculated before and after voluntary voiding as mL of urine = 0.2 × W × L × W × (H1 + H2)/2 where L = sagittal length, W = transverse width, H1 = sagittal height, and H2 = transverse height. The uVol at each time point was calculated as the total volume of urine obtained by free catch and cystocentesis. If the dog urinated in the cage prior to the specific time point, the cage bedding was weighed, and for each gram greater than the dry weight of the bedding, 1 mL of urine was added to the time point’s total. Water was provided ad libidum during the
study and water consumption recorded. Total uVol over the 7-hour study period (mL/kg/7 h) was calculated as the sum of uVol at 180, 270, and 420 minutes, minus the bladder volume by ultrasound at baseline and added to the bladder volume by ultrasound remaining at 420 minutes, divided by body weight. Total uNa output (mEq/kg/7 h) was calculated as the sum of uVol × [uNa] at each timepoint and divided by body weight. Electrolyte free water clearance (EFWC), a unitless value that represents renal free water excretion, was calculated as uVol/(EFWC), a unitless value that represents renal free water excretion, at 420 minutes, divided by body weight. Total uNa output and uVol were predicted by modifying an equation that was developed to quantify 6-hour uVol and uNa output in dogs. The physiologic principles of urine formation are the same in the presence or absence of disease, and we included both healthy and CHF dogs in our study in order to validate the equation over a wide range of uNa and uVol values. In addition, we also sought to explore potential metrics for LDR. Accordingly, 5 different definitions of LDR, adapted from guidelines in humans and studies in experimental dogs, were constructed (Table 1). The number of criteria fulfilled by each dog was tabulated, and we arbitrarily defined LDR as dogs fulfilling ≥3 criteria. Based on this definition, we further hypothesized that predicted uNa and uVol would discriminate dogs with and without suspected LDR with high sensitivity and specificity. Pilot work in healthy dogs performed by the investigators revealed unexpectedly low uVol after furosemide dosing in some dogs (unpublished data), and we hypothesized that stress, reluctance to...
drink water, and sympathetic nervous system and RAAS activation while in-hospital could temporarily induce LDR31 and that a wide range of uNa outputs and uVol might exist in both healthy and CHF dogs undergoing the study protocol.

2.2 | Statistical methods

Descriptive data were reported for normality using Kolmogorov-Smirnov tests and reported as mean (SD) for parametric data or median (range) for nonparametric data. Baseline differences between healthy and CHF dogs were tabulated and compared using t tests, Mann-Whitney U, and Fisher’s exact tests. Differences of longitudinal data across study timepoints were assessed using 1-way analysis of variance or Friedman’s tests followed by Holm-Sidak’s or Dunn’s multiple comparison tests, respectively. Correlation between observed and predicted uNa using Equations (2) and (3) and observed and predicted uVol using Equations (4) and (5) was performed by calculation of Pearson’s r or Spearman’s rs. Strength of correlation was described as very high, high, moderate, low, and negligible for r or rs values of 0.9-1.0, 0.7-0.89, 0.5-0.69, 0.3-0.49, and 0-0.29, respectively.32 The suitability of the a priori selection of equation constants was tested by post hoc calculation of constants that minimized the sum of squares between the observed and predicted uNa and uCr. Receiver operating characteristic (ROC) curves and their areas under the curve (AUC) were used to determine the sensitivity and specificity of the prediction equations to identify suspected DR dogs. Univariable linear or logistic regression was performed to explore the effect of dietary Na, presence or absence of heart disease, age, body weight, blood pressure, PCV, and baseline [sCr], BUN, [sNa], [sCl], and [sK] on total uNa output. Because of the small number of dogs, multivariable regression was not performed. Box and whisker plots display the median value (line), IQR (box), and 1.5 times the IQR above and below the 75th and 25th percentile values, respectively (whiskers). Statistical calculations were performed using software (Excel for Mac v16.28, Microsoft Corp., Redmond, Washington; Prism 8.3.0, GraphPad Software, La Jolla, California). Statistical significance was P < .05.

3 | RESULTS

3.1 | Study cohort

Fourteen dogs, including 8 healthy and 6 CHF dogs, were recruited. Baseline data, including comparisons between healthy and CHF dogs, is shown in Table 2. Dog breeds included 6 mixed breed, 2 Labrador Retrievers, 2 Cavalier King Charles Spaniels, and 1 Golden Retriever, American Pit Bull Terrier, Shiba Inu, and Boxer. Four dogs had degenerative mitral valve disease and 2 dogs had dilated cardiomyopathy.

3.2 | Furosemide natriuresis and diuresis

Furosemide induced natriuresis and diuresis in a time-dependent fashion in the study cohort (Figure 1). Hourly rate of uNa excretion was greatest from 0 to 180 minutes as compared to 180 to 270 minutes and 270 to 420 minutes (Figure 1A). Hourly uVol was greatest from 180 to 270 minutes as compared to 0 to 180 minutes and 270 to 420 minutes (Figure 1B). Over the 7-hour study duration, average total uNa output was 2.63 mEq/kg (SD, 1.44 mEq/kg) and average total uVol was 23.5 mL/kg (SD, 9.68 mL/kg). There was a significant and moderate linear correlation between observed uNa output versus observed uVol (r = 0.643, [95% confidence interval [CI], 0.170-0.875], P = .01) (Figure 2). Three CHF dogs noticeably departed from the relationship and were characterized as excreting relatively large cumulative uVol with low uNa output. There were no significant differences in 7-hour uNa output or uVol between healthy and CHF dogs (Figure 3). The eGFR was not significantly different between timepoints (baseline: 2.51 mL/min/kg [SD, 0.69 mL/min/kg]; 180 minutes: 2.40 mL/min/kg [SD, 0.62 mL/min/kg]; 270 minutes: 2.43 mL/min/kg [SD, 0.65 mL/min/kg], P = .07). Baseline [sCr] (r = −0.59, P = .02) was moderately correlated with cumulative uNa output. The remainder of the baseline characteristics were not significantly associated with total uNa output, including, BUN (r = 0.52, P = .06), presence or absence of CHF (r = 0.30, P = .29), age (r = 0.37, P = .19), body weight (r = 0.17, P = .54), blood pressure (r = 0.14, P = .60), [sNa] (r = 0.17,

### Table 1
Five a priori criteria for low diuretic responsiveness in study dogs administered oral furosemide based on modifications of criteria or data in humans and purpose-bred dogs.

| Human or experimental criterion | Modified study criterion |
|--------------------------------|--------------------------|
| 1. Spot [uNa] <50-70 mEq/L in first 2 hours after diuretic administration10 | 1. Spot [uNa] <60 mEq/L in first 3 hours after diuretic administration |
| 2. Spot [uNa]:[uK] ratio <1 during first 6 hours after diuretic administration29 | 2. Spot [uNa]:[uK] ratio <1 during first 7 hours after diuretic administration |
| 3. uVol <100-150 mL/person/h (~1.5 mL/kg/h) over any hour during the first 6 hours after diuretic administration | 3. uVol <1.5 mL/kg/h over any hour during first 7 hours after diuretic administration |
| 4. Purpose-bred dogs had uNa output of 2.3-6 mEq/kg/24 h following furosemide 2 mg/kg PO qd16 | 4. Total uNa output/kg <1.0 mEq/kg over first 7 hours after diuretic administration |
| 5. Successful decongestion involves net fluid loss7,30,31 | 5. Net positive water gain over first 7 hours after diuretic administration |

Abbreviations: uNa, urinary sodium; [uNa], urinary sodium concentration; [uNa]:[uK], urinary sodium to urinary potassium concentration ratio; uVol, urine volume.
TABLE 2  Characteristics of the study population

|                                | Healthy (n = 8) | Heart disease (n = 6) | P   |
|--------------------------------|----------------|----------------------|-----|
| Age (years)                    | 6.3 (2.5)      | 9.5 (1.7)            | .02 |
| Sex (M/F)                      | 4/4            | 6/0                  | .08 |
| Body weight (kg)               | 17.3 (6.0)     | 22.9 (15.7)          | .41 |
| Breeds                         | Mixed, n = 4   | Mixed, n = 2         |     |
|                               | Pitbull Terrier| CKCS, n = 2          |     |
|                               | Shiba Inu      | Boxer                |     |
|                               | Labrador Retriever | Labrador Retriever |     |
|                               | Golden Retriever |                     |     |
| BCS                            | 5 (5-5)        | 5.5 (5-6.25)         | .06 |
| Blood pressure (mm Hg)         | 136 (16)       | 121 (16)             | .12 |
| Dietary Na of morning meal (mg/kg) | 15.3 (12.8-21.8) | 10.0 (0-57.2) | .14 |
| Time from meal to furosemide administration (mins) | 130 (56) | 105 (53) | .45 |
| Baseline laboratory value      |                |                      |     |
| PCV (%)                        | 49 (4)         | 45 (5)               | .16 |
| BUN (mg/dL)                    | 16 (3)         | 23 (8)               | .04 |
| Creatinine (mg/dL)             | 1.0 (0.2)      | 1.2 (0.4)            | .22 |
| eGFR (mLs/min/kg)              | 2.64 (0.59)    | 2.32 (0.83)          | .41 |
| Serum Na (mEq/L)               | 145 (2)        | 143 (2)              | .20 |
| Serum Cl (mEq/L)               | 115 (2)        | 108 (2)              | <.0001 |
| Serum K (mEq/L)                | 4.3 (0.3)      | 4.6 (0.4)            | .10 |
| USG                            | n = 6, 1.037 (1.016-1.040) | 1.013 (1.006-1.025) | .009 |
| Urine Na (mEq/L)               | n = 6, 75 (79) | 30 (25)              | .22 |
| Urine K (mEq/L)                | n = 6, 117 (69-261) | 37 (20-117) | .02 |
| Urine creatinine (mg/dL)       | n = 6, 248 (104-343) | 47 (43-174) | .004 |
| Cardiac medications            |                |                      |     |
| Furosemide (mg/kg/d)           | NA             | n = 6, 3.7 (1.0)    |     |
| ACEI (mg/kg/d)                 | NA             | n = 6, 5, 0.79 (0.21) |     |
| Enalapril                      | NA             | n = 1, 0.38         |     |
| Benazepril                     | NA             | n = 6, 2.1 (0.8)    |     |
| Spironolactone (mg/kg/d)       | NA             | n = 6, 6.0 (0.09)   |     |
| Pimobendan (mg/kg/d)           | NA             |                      |     |

Abbreviations: ACEI, angiotensin converting enzyme inhibitor; BCS, body condition score; BUN, blood urea nitrogen; Cl, chloride; eGFR, estimated glomerular filtration rate; F, female; K, potassium; M, male; Na, sodium; NA, not applicable; USG, urine specific gravity.

\[ P = .57, \text{[sCl]} (r = 0.15, P = .63), \text{[sK]} (r = 0.04, P = .87)\), and PCV \((r = 0.24, P = .38)\) were significantly and moderately correlated to observed total uVol (Figure 5).

3.3 | Prediction of cumulative uNa output and uVol using spot urine samples

Predicted 7-hour uNa output using spot samples at 180 minutes \(r_s = 0.763, [95\% CI, 0.375-0.923]\), \(P = .002\) and 270 minutes \(r_s = 0.816, [95\% CI, 0.503-0.940]\), \(P < .001\) were both significantly and highly correlated to observed uNa output (Figure 4). Predicted uVol using spot samples at 180 minutes \(r_s = 0.598, [95\% CI, 0.098-0.857]\), \(P = .02\) and 270 minutes \(r_s = 0.791, [95\% CI, 0.450-0.931]\), \(P < .001\) were significantly and highly correlated to observed total uVol (Figure 5).

3.4 | Prediction of diuretic responsiveness

Five of 14 (36%) dogs met ≥3 criteria for LDR, including 2 healthy dogs and 3 CHF dogs. The numbers of dogs fulfilling each of the 5 LDR criteria are presented in Table 3.

Spot [uNa] at 180 minutes in the 5 suspected DR dogs was 61 mEq/L (SD, 38 mEq/L) and was significantly lower compared to that of the remaining 9 dogs (153 mEq/L [SD, 32 mEq/L], \(P < .001\)). The [uNa]:[uK] ratio was highly and significantly correlated with uVol.
(180 minutes: $r = 0.731$, $P = .003$; 270 minutes: $r = 0.747$, $P = .002$) and $[\text{uNa}]:[\text{uK}]$ was lower in dogs with LDR (1.49 [SD, 0.70]) versus non-LDR dogs (3.36 [SD, 0.80], $P < .001$) over the 7-hour study duration. The uNa output of LDR dogs (0.99 mEq/kg [SD, 0.62 mEq/kg]) was significantly lower than non-LDR dogs (3.54 mEq/kg [SD, 0.74 mEq/kg], $P < .001$) (Figure 6A). The uVol in LDR dogs (17.5 mL/kg, [SD, 11.1 mL/kg]) was lower than non-LDR dogs (26.8 mL/kg [SD, 7.4 mL/kg]) but this difference was not significantly different ($P = .08$) (Figure 6B). Dogs with LDR excreted more free water as evidenced by significantly greater EFWC at 180 minutes (LDR dogs, 103.2 mL/kg [SD, 174.3 mL/kg]) versus non-LDR dogs, −58.0 [SD, 42.9], $P = .02$) and 270 minutes (LDR dogs, 70.3 [SD, 108.6] versus non-LDR dogs, −33.8 [SD, 28.5], $P = .02$). Net fluid balance was significantly and negatively correlated to uNa such that dogs with net fluid gain excreted less uNa ($r = −0.710$, $P = .006$) (Figure 7). Dogs drank an average of 21 mL water/kg (range, 1.8-66 mL/kg) during the study duration. Dogs with LDR experienced a net positive median water gain (9.0 mL/kg [range, −2.5 to 53.7 mL/kg]) versus remaining dogs.
Median dietary Na intake the morning of the study was 0.59 mEq/kg (range, 0-2.49 mEq/kg) and there was moderate and significant correlation between dietary Na intake and cumulative uNa output ($r = 0.68$, $P = .01$). Median net Na balance was $-2.02$ mEq/kg (range, $-3.56$ to $0.31$ mEq/kg) with 1 dog experiencing a net gain. Dogs suspected as having LDR had significantly less net Na loss than other dogs (LDR: $-0.63$ mEq/kg [SD, 0.68 mEq/kg] versus with no LDR: $-2.66$ mEq/kg [SD, 0.78 mEq/kg], $P < .001$). The baseline sNa, sCl, and sK between dogs with and without LDR were not significantly different (data not shown).

### 3.5 | Identification of dogs with and without LDR

Receiver-operating characteristic curves were used to assess the ability of predicted uNa and uVol to differentiate the 5 LDR dogs (Figure 8). Predicted uNa at 180 and 270 minutes possessed AUC of 0.933 (95% CI, 0.804-1.000, $P = .01$) and 0.911 (95% CI, 0.756-1.000, $P = .01$), respectively. Predicted uVol at 180 and 270 minutes...
possessed AUC of 0.644 (95% CI, 0.315-0.975, \(P = .39\)) and 0.744 (95% CI, 0.466-1.000, \(P = .14\)), respectively. Post hoc constants for uNa output and uVol equations were calculated as 0.55 and 599, respectively, compared favorably to a priori values, and did not significantly change the AUCs of the ROC analysis (data not shown).

4 | DISCUSSION

The main result of our study was the validation of equations based on spot urine sampling at 180 and 270 minutes to predict 7-hour cumulative uNa output and uVol in response to oral furosemide administration. The methodology and results of this study closely mirrored results in humans with CHF\(^{18}\) and support the validity of the underlying basic physiological principles upon which the equations were based. In both studies, the correlation between the observed and predicted uNa was high and strong enough to identify subjects with poor diuretic response versus those with more robust responses. The findings of our study have important clinical implications. It has long been known that dogs with CHF possess greatly increased total body Na and extracellular water content.\(^{33}\) Thus, clinical assessment of diuretic responsiveness, particularly uNa output, could help individualize CHF therapy beyond what is currently performed.\(^{6,10,19,34}\)

An important feature of our study was the focus on uNa output, which, as opposed to uVol or water or weight loss, has been increasingly recognized as the best index of diuretic responsiveness and predictor of important clinical outcomes.\(^{8,10,18,35-41}\) Natriuresis and diuresis, while closely intertwined, are distinct aspects of diuretic responsiveness, and play related but different roles in the clinical assessment of efficacy. The varied relationship between cumulative
uNa and uVol as shown in Figure 2 highlights the fact that these measures are not interchangeable. It does not necessarily follow that dogs excreting high uVol also excrete high uNa. In humans, clinical assessment after diuretics traditionally involves relief of symptoms, such as dyspnea, net water or weight loss, and evidence of volume depletion such as hemococoncentration\(^7\),\(^10\) however, substantial congestion can persist despite meeting these criteria\(^4\),\(^3\). In dogs, diuretic decongestion also is primarily guided by fluid loss and symptomatic relief\(^6\) yet, in both species, it is extremely difficult to disentangle decongestion (i.e., removal of water and Na from the extracellular space) from dehydration (i.e., removal of water from the intravascular or intracellular space) when basing response on uVol or net water loss alone. As previously mentioned, water balance in extracellular spaces, such as the pulmonary interstitium, is primarily controlled by extracellular NaCl, which makes up over 90% of the extracellular solute.\(^3\) Water freely diffuses between the extracellular and intracellular spaces according to the osmotic gradient. The most efficient decongestion ideally involves urine that is isotonic (i.e., \(\sim 140\) mEq/mL) or hypertonic to plasma so that extracellular fluid is removed without depleting intracellular fluid.\(^4\) Excessive loss of water with low solute (i.e., excessive free water excretion) without concomitant net loss of Na can ultimately result in incomplete decongestion, recurrent edema, and increased mortality.\(^3\),\(^4\),\(^5\) The futility of long-term low-solute diuresis is evidenced by the inability of vasopressin antagonists, which promote free water excretion, to reduce mortality.\(^4\) Thus, while uVol and net fluid loss are important components of the diuretic response, the ultimate measure of diuretic responsiveness is maintenance of Na balance in the extracellular space and forced natriuresis in the face of increased renal Na avidity.\(^4\) The direct line from extracellular Na to extracellular water gives uNa output more “biologic plausibility” as a measure of diuretic responsiveness than fluid loss.\(^9\)

Diuretic responsiveness from the standpoint of diuretic-induced activation of RAAS, uNa excretion, and prediction of uVol has been studied.\(^1\),\(^4\) In healthy dogs receiving constant rate infusion of furosemide, hourly uNa output and [uNa]:[uK] were strongly correlated with hourly uVol (uNa versus uVol: \(r = 0.996, P < .0001\); [uNa]:[uK]

---

**FIGURE 8**  Receiver-operating characteristic curves for the detection of 5 dogs with low diuretic responsiveness (LDR) based on urinary Na (uNa) output and urine volume (uVol) predicted from equations using spot urine sample at 180 minutes (T180) and 270 minutes (T270) after oral furosemide dosing. AUC, area under the curve.
versus uVol: \( r = 0.976, P < .001 \) highlighting the close relationship between Na and uVol, under what might be considered optimal conditions.\(^7\) In our study, the correlation between cumulative uNa output and uVol was comparatively less (\( r = 0.643 \)) and highlighted how uNa and uVol can become disconnected, particularly in dogs with CHF. Specifically, 3 dogs noticeably departed from the main uNa to uVol relationship, all excreting relatively large volumes of Na-poor urine. To clinicians and owners, the large uVol after dosing might be interpreted as a sign of good diuretic response, however, primarily because of a combination of low uNa and poor net water loss—and in some instances net water gain (Figure 7)—all 3 of these dogs met criteria for LDR. The low uNa:uVol ratio might be caused by kidney phenomena such as medullary washout or compulsive water consumption, which 1 of the 3 dogs appeared to exhibit during the study period. Thus, results of our study expand existing knowledge by demonstrating how consideration of uNa output and uVol in tandem can help better identify individuals with LDR.

Diuretic responsiveness is complex and a result of many pharmacokinetic, pharmacodynamic, physiological, and dietary variables, including oral bioavailability, tubular secretion, kidney function, neurohormonal activation, and dietary Na intake. Poor responsiveness from any or all of these reasons could be considered forms of LDR. In dogs, specific criteria for LDR are lacking, and further study is warranted. In humans, criteria vary, and no standard definition exists.\(^10,36\) The most intriguing criteria are associated with important clinical outcomes, such as increased mortality or hospital admission.\(^9\) For instance, in humans with acute CHF, uNa <60 mEq/L is associated with a significantly increased risk of death, rehospitalization, need for mechanical circulatory support, or home-based IV inotropic therapy compared to those with greater [uNa].\(^39,45\) In our study, similar to those in humans,\(^28\) we supposed LDR based on fulfillment of multiple criteria involving a combination of uNa output, uVol, and net water balance, rather than a single criterion. In our study, our chief aim was to validate a method to quantify responsiveness using spot samples. Our study was neither designed to validate a definition of LDR nor to differentiate specific causes, however, several of our findings related to LDR bear mention. Firstly, the changes in uVol and uNa that accompany LDR are mediated through GFR and the tubular concentration or dilution. While GFR and sCr:uCr might quantitatively change, the governing principles of urine formation expressed in the prediction methods do not, which permits detection of low responsiveness by our methods independent of underlying cause and in both health and disease. Secondly and relatedly, 2 healthy dogs met criteria for LDR, which was consistent with our pilot experience with healthy dogs. Low diuretic responsiveness also has described in healthy humans consuming a low salt diet.\(^48\) In our study, we hypothesized that stress and increased sympathetic and RAAS activity related to hospitalization and the study procedures blunted the diuretic response.\(^31\) In the current study, 2 healthy dogs were suspected with LDR and were the only dogs in the overall cohort that demonstrated [uNa]:[uK] <1 over multiple timepoints, suggesting high RAAS activity.\(^13\) Thirdly, the specific relationship between uNa and uVol in subjects with low LDR might offer clues as to underlying etiology that can be further studied. For instance, low uNa coupled with low uVol is more suggestive of low bioavailability, low Na intake, and high RAAS activity, whereas low uNa coupled with high uVol suggests medullary washout, distal tubular hypertrophy, excessive vasopressin release, or high amounts of free water intake. A fourth important consideration is that selection of specific criteria to define LDR affects the predictive ability of related metrics. In our study, we employed a mixture of LDR criteria involving both uNa and uVol to try and avoid biasing the ROC analysis towards either metric, yet, the predictive ability of uNa was substantially greater than that of uVol, supporting the important role of Na in diuretic responsiveness. A fifth important consideration relevant to LDR is dietary Na, which has the potential to profoundly affect the natriuretic response to diuretics.\(^48,49\) In our study, dietary Na intake was moderately correlated to 7-hour uNa output, and dogs had consumed a wide range of dietary Na the morning of the study. In humans, dietary Na can be standardized, which better allows for better definition and detection of LDR based solely on uNa output.\(^18\) In circumstances where dietary Na is not standardized, LDR based on net Na balance (i.e., uNa output minus dietary Na intake) might be a better indicator of responsiveness.

There are important potential limitations of our study, some of which have been previously mentioned. The subject number was small and confidence intervals around estimates were wide, reflecting the omnipresent challenge of cohort size in veterinary trials, especially those that involve laborious methodology, such as in our study. We might not have had sufficient power to detect important differences between groups. We used eGFR rather than measuring GFR using iothalamol. Our privately owned dogs did not undergo bladder catheterization as has been done in purpose-bred dogs and hourly estimations of uNa output and uVol represented the average value within the timeframes represented by each particular sampling period. The absence of bladder catheterization also increased the risk of spilled or missed uVol, however, we attempted to minimize this to the extent possible. Our study has important practical implications insofar as our spot urine sample obtained at 180 minutes represents urine produced from 0 to 180 minutes, with the dog’s bladder as empty as possible prior to dosing. Similarly, when obtaining a spot urine sample representing 270 minutes, the dog’s bladder at 180 minutes should be as empty as possible. Urine and Na loss from a dog voiding at times other than at 0 and 180 could affect spot results if the urine composition substantially changes from the start of the window of accumulation to the end of the window. Despite these limitations, the proposed methodology using spot samples is far easier and practical to perform in a clinical setting than attempting collection of urine produced over 7 hours. The criteria for LDR used in our study are best viewed as a starting point for further study and validation. For instance, the fact that cumulative uNa <2 mEq/kg was sensitive and specific to our LDR dogs could help formulate LDR hypotheses for future testing. Our study identified dogs with LDR but did not differentiate any of the potential pharmacologic, pharmacodynamic, renal or neurohormonal causes of LDR. As currently regarded in humans, the pathophysiology of and criteria for LDR tilt in favor of uNa output...
as the metric of prime importance with less emphasis on uVol. In our study, the greater strength of correlation between predicted and observed uNa, as compared to predicted and observed uVol, facilitates consideration of uNa output. The potential effect of dietary Na on diuretic responsiveness has already been mentioned. An additional limitation involving dietary Na was the fact that time between feeding and diuretic dosing was not consistent amongst dogs. Water consumption amongst dogs varied considerably and might have contributed to the lag in peak uVol formation versus uNa excretion, and specific studies of water consumption habits in dogs receiving diuretics are of interest. Our study examined dogs with chronic CHF rather than acute CHF, and diuretic responsiveness in humans with chronic CHF is less understood than in acute CHF. However, as previously stated, the basic renal principles governing urine formation and uNa output used in the prediction equations are the same in chronic CHF as in acute CHF, as well as in the healthy subject. One uNa measurement specific to chronic CHF that warrants further investigation is using spot [uNa] to predict impending decomposition. In a study of humans with chronic CHF, [uNa] from first morning void was persistently lower in the patient cohort that experienced future decomposition, and spot [uNa] further dropped by another 35% in the week prior to decomposition. Finally, the prediction equations validated in our study are specific to 3 mg/kg PO furosemide and urine sampling at the prescribed timepoints. Diuretic responsiveness to parenteral furosemide dosing or treatment with other diuretic drugs requires additional study.

In conclusion, we validated a priori physiological equations to predict cumulative uNa output ([uNa [mEq/kg] = [uNa/uCr] × 0.507) and uVol (uVol [mL/kg] = 1/[uCr] × 507) over the 7 hours after 3 mg/kg PO furosemide administration in healthy and CHF dogs. Urinary Na excretion and uVol are complementary but distinct aspects of diuretic responsiveness and predicted uNa output demonstrated better correlation to observed uNa as well as greater ability to identify dogs with LDR than did predicted uVol. The ability to quantify diuretic responsiveness opens doors to many different avenues of further inquiry, including understanding of the pathophysiology of DR, validation of dog-specific criteria for LDR, individualization of diuretic dosing based on dietary Na and net Na balance, detection of impending decomposition in apparently stable dogs, comparative effectiveness of different loop diuretics and dosing regimens, as well as strategies to improve or restore effectiveness in dogs with LDR.

ACKNOWLEDGMENT
No funding was received for this study. The authors thank the owners who volunteered their dogs for this study.

CONFLICT OF INTEREST DECLARATION
Authors declare no conflict of interest.

OFF-LABEL ANTIMICROBIAL DECLARATION
Authors declare no off-label use of antimicrobials.

INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) OR OTHER APPROVAL DECLARATION
University of Pennsylvania IACUC approval, #806527.

HUMAN ETHICS APPROVAL DECLARATION
Authors declare human ethics approval was not needed for this study.

ORCID
Mark A. Oyama https://orcid.org/0000-0002-5218-9226

REFERENCES
1. Parrinello G, Greene SJ, Torres D, et al. Water and sodium in heart failure: a spotlight on congestion. Heart Fail Rev. 2015;20:13-24.
2. Anand IS, Ferrari R, Kalra GS, et al. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation. 1989;80:299-305.
3. Roumeliotis ME, Glew RH, Khitan ZJ, et al. Fluid balance concepts in medicine: principles and practice. World J Nephrol. 2018;7:1-28.
4. Nijst P, Verbrugge FH, Grienet L, et al. The pathophysiological role of interstitial sodium in heart failure. J Am Coll Cardiol. 2015;65:378-388.
5. Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017;377:1964-1975.
6. Keene BW, Atkins CE, Bonagura JD, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med. 2019;33:1127-1140.
7. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810-1852.
8. Singh D, Shrestha K, Testani JM, et al. Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure. J Card Fail. 2014;20:392-399.
9. Verbrugge FH. Editor’s choice-diuretic resistance in acute heart failure. Eur Heart Jour Acute Cardiovasc Care. 2018;7:379-389.
10. Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:137-155.
11. Testani JM, Brisco MA, Turner JM, et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail. 2014;7:261-270.
12. Kiernan MS, Stevens SR, Tang WHW, et al. Determinants of diuretic responsiveness and associated outcomes during acute heart failure hospitalization: an analysis From the NHLBI Heart Failure Network Clinical Trials. J Card Fail. 2018;24:428-438.
13. Adin D, Atkins C, Papich MG. Pharmacodynamic assessment of diuretic efficacy and braking in a furosemide continuous infusion model. J Vet Cardiol. 2018;20:92-101.
14. Potter BM, Ames MK, Hess A, et al. Comparison between the effects of torsemide and furosemide on the renin-angiotensin-aldosterone system of normal dogs. J Vet Cardiol. 2019;26:51-62.
15. Hori Y, Takusagawa F, Ikada H, et al. Effects of oral administration of furosemide and torsemide in healthy dogs. Am J Vet Res. 2007;68:1058-1063.
16. Uechi M, Matsuoka M, Kuwajima E, et al. The effects of the loop diuretics furosemide and torasemide on diuresis in dogs and cats. J Vet Med Sci. 2003;65:1057-1061.
17. Adin D, Kurtz K, Atkins C, et al. Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease. J Vet Intern Med. 2020;34:53-64.
18. Testani JM, Hanberg JS, Cheng S, et al. Rapid and highly accurate prediction of poor loop diuretic natriuretic response in patients with heart failure. *Circ Heart Fail*. 2016;9:e002370.

19. Felker GM, Ellison DH, Mullens W, et al. Diuretic therapy for patients with heart failure: JACC state-of-the-art review. *J Am Coll Cardiol*. 2020;75:1178-1195.

20. Aronson D, Burger AJ. Diuretic Response: Clinical and hemodynamic predictors and relation to clinical outcome. *J Card Fail*. 2016;22:193-200.

21. Ter Maaten JM, Dunning AM, Valente MA, et al. Diuretic response in acute heart failure—an analysis from ASCEND-HF. *Am Heart J*. 2015;170:313-321.

22. Atalan G, Barr FJ, Holt PE. Assessment of urinary bladder volume in dogs by use of linear ultrasonographic measurements. *Am J Vet Res*. 1998;59:10-15.

23. Lisciandro GR, Fosgate GT. Use of urinary bladder measurements from a point-of-care cysto-colic ultrasonographic view to estimate urinary bladder volume in dogs and cats. *J Vet Emerg Crit Care*. 2017;27:713-717.

24. Bodonyi-Kovacs G, Lecker SH. Electrolyte-free water clearance: a key to the diagnosis of hyponatremia in resolving acute renal failure. *Clin Exp Nephrol*. 2008;12:74-78.

25. Finco DR, Brown SA, Vaden SL, et al. Relationship between plasma creatinine concentration and glomerular filtration rate in dogs. *J Vet Pharmacol Ther*. 1995;18:418-421.

26. Hall JE. The urinary system: functional anatomy and urine formation by the kidneys. *Guyton and Hall Textbook of Medical Physiology*. 13th ed. Philadelphia, PA: Elsevier; 2016:323-333.

27. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150:604-612.

28. Doering A, Jenkins CA, Storrow AB, et al. Markers of diuretic resistance in emergency department patients with acute heart failure. *Int J Emerg Med*. 2017;10:17.

29. Testani JM, Brisco MA, Kociol RD, et al. Substantial discrepancy between fluid and weight loss during acute decompensated heart failure treatment. *Am J Med*. 2015;128:776-783.e774.

30. Simonavicius J, Knackstedt C, Brunner-La Rocca HP. Loop diuretics in chronic heart failure: how to manage congestion? *Heart Fail Rev*. 2019;24:14-30.

31. Sobotka PA, Mahfoud F, Schlaich MP, et al. Sympatho-renal axis in chronic disease. *Clin Res Cardiol*. 2011;100:1049-1057.

32. Hinkle DE, Wiersma W, Jurs SG. *Applied Statistics for the Behavioral Sciences*. 5th ed. Boston, MA: Houghton Mifflin; 2003.

33. Conn HL Jr, Dettweiler DK, McGiff J, et al. Why we have gone to the dogs. *Am Clin Climatol Assoc*. 1966;77:34-47.

34. Damman K, Ter Maaten JM, Coster JE, et al. Clinical importance of urinary sodium excretion in acute heart failure. *Eur J Heart Fail*. 2020;22:1438-1447. https://doi.org/10.1002/ejhf.1753.

35. Collins SP, Jenkins CA, Baugham A, et al. Early urine electrolyte patterns in patients with acute heart failure. *ESC Heart Fail*. 2019;6:80-88.

36. Gupta R, Testani J, Collins S. Diuretic resistance in heart failure. *Curr Heart Fail Rep*. 2019;16:57-66.

37. Martens P, Dupont M, Verbrugge FH, et al. Urinary sodium profiling in chronic heart failure to detect development of acute decompensated heart failure. *JACC Heart Fail*. 2019;7:404-414.

38. Biegus J, Zymlinski R, Sokolski M, et al. Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure. *Eur J Heart Fail*. 2019;21:633–634.

39. Brinkley DM Jr, Burpee LJ, Chaudhry SP, et al. Spot Urine Sodium as Triage for Effective Diuretic Infusion in an Ambulatory Heart Failure Unit. *J Card Fail*. 2018;24:349-354.

40. Desai AS, McCausland FR. Urinary sodium as a heart failure biomarker: more complicated than it seems. *JACC Heart Fail*. 2019;7:415-417.

41. Verbrugge FH, Dupont M, Steels P, et al. The kidney in congestive heart failure: “are natriuresis, sodium, and diuretics really the good, the bad and the ugly?”. *Eur J Heart Fail*. 2014;16:133-142.

42. Rubio-Gracia J, Demissei BG, Ter Maaten JM, et al. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. *Int J Cardiol*. 2018;258:185-191.

43. Lala A, McNulty SE, Mentz RJ, et al. Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from diuretic optimization strategy evaluation in acute decompensated heart failure (DOSE-AHF) and cardiorenal rescue study in acute decompensated heart failure (CARESS-HF). *Circ Heart Fail*. 2015;8:741-748.

44. Costanzo MR, Jessup M. Treatment of congestion in heart failure with diuretics and extracorporeal therapies: effects on symptoms, renal function, and prognosis. *Heart Fail Rev*. 2012;17:313-324.

45. Luk A, Groarke JD, Desai AS, et al. First spot urine sodium after initial diuretic identifies patients at high risk for adverse outcome after heart failure hospitalization. *Am Heart J*. 2018;203:95-100.

46. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. *J Amer Med Assoc*. 2007;297:1319-1331.

47. Hagstrom J, Hansson K, Karlberg BE, et al. Effects of long-term treatment with enalapril or hydrozaline on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation. *Am J Vet Res*. 1996;57:1645-1652.

48. Wilcox CS, Mitch WE, Kelly RA, et al. Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. *J Lab Clin Med*. 1983;102:450-458.

49. Brater DC. Diuretic therapy. *N Engl J Med*. 1998;339:387-395.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Loughran KA, Larouche-Lebel É, Huh T, Testani JM, Rao VS, Oyama MA. Prediction and measurement of diuretic responsiveness after oral administration of furosemide to healthy dogs and dogs with congestive heart failure. *J Vet Intern Med*. 2020;34:2253-2264. https://doi.org/10.1111/jvim.15952